DK1163008T3 - Anvendelse af trehalose til stabilisering af en flydende vaccine - Google Patents

Anvendelse af trehalose til stabilisering af en flydende vaccine

Info

Publication number
DK1163008T3
DK1163008T3 DK00912734T DK00912734T DK1163008T3 DK 1163008 T3 DK1163008 T3 DK 1163008T3 DK 00912734 T DK00912734 T DK 00912734T DK 00912734 T DK00912734 T DK 00912734T DK 1163008 T3 DK1163008 T3 DK 1163008T3
Authority
DK
Denmark
Prior art keywords
trehalose
liquid vaccine
stabilize
vaccine composition
liquid
Prior art date
Application number
DK00912734T
Other languages
English (en)
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK1163008T3 publication Critical patent/DK1163008T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00912734T 1999-03-23 2000-03-23 Anvendelse af trehalose til stabilisering af en flydende vaccine DK1163008T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (fr) 1999-03-23 1999-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide
PCT/FR2000/000730 WO2000056365A1 (fr) 1999-03-23 2000-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide

Publications (1)

Publication Number Publication Date
DK1163008T3 true DK1163008T3 (da) 2003-11-17

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912734T DK1163008T3 (da) 1999-03-23 2000-03-23 Anvendelse af trehalose til stabilisering af en flydende vaccine

Country Status (11)

Country Link
EP (1) EP1163008B1 (da)
JP (1) JP2002540079A (da)
AT (1) ATE246937T1 (da)
AU (1) AU3438900A (da)
CA (1) CA2366869A1 (da)
DE (1) DE60004496T2 (da)
DK (1) DK1163008T3 (da)
ES (1) ES2200845T3 (da)
FR (1) FR2791895B1 (da)
PT (1) PT1163008E (da)
WO (1) WO2000056365A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
WO2008028957A2 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
BR112012022688A2 (pt) 2010-03-10 2018-05-22 Glaxosmithkline Biologicals Sa proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
US20120294894A1 (en) 2011-05-20 2012-11-22 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
FR2992656B1 (fr) * 2012-07-02 2016-10-07 Sanofi Pasteur Procede de production d'antigenes haemophilus influenzae type b
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
WO2014100853A1 (en) 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018048869A1 (en) 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
CA3054861A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Peptide vaccines
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
JP2021536487A (ja) 2018-09-04 2021-12-27 トレオス バイオ リミテッド ペプチドワクチン
EP3876982A1 (en) 2018-11-06 2021-09-15 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
KR20230017373A (ko) 2020-04-03 2023-02-03 펩티씨 백신즈 리미티드 코로나바이러스 백신
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
EP0626452B1 (en) * 1993-05-17 1999-08-11 Akzo Nobel N.V. Vaccine against Streptococcus suis infection
ATE235919T1 (de) * 1994-06-02 2003-04-15 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
DK0939648T3 (da) * 1996-09-26 2008-02-11 Merck & Co Inc Rotavirusvaccineformuleringer
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
EP1163008A1 (fr) 2001-12-19
PT1163008E (pt) 2003-12-31
DE60004496D1 (de) 2003-09-18
AU3438900A (en) 2000-10-09
JP2002540079A (ja) 2002-11-26
ES2200845T3 (es) 2004-03-16
CA2366869A1 (en) 2000-09-28
FR2791895A1 (fr) 2000-10-13
DE60004496T2 (de) 2004-04-08
EP1163008B1 (fr) 2003-08-13
ATE246937T1 (de) 2003-08-15
FR2791895B1 (fr) 2001-06-15
WO2000056365A1 (fr) 2000-09-28

Similar Documents

Publication Publication Date Title
DK1163008T3 (da) Anvendelse af trehalose til stabilisering af en flydende vaccine
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK1914244T3 (da) Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE60007095T2 (de) Calanolide zur hemmung von btk
DE60125797D1 (de) Impfstoffzusammesetzung
FI20012281A0 (fi) Menetelmä ja järjestelmä personoitujen sanomien synnyttämiseksi
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1235579T3 (da) Farmaceutiske præparater med indhold af trimegeston
DE69836976D1 (de) Neospora impstoff
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
BR0110205A (pt) Inibidores de peptìdeo deformilase
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
ATE255594T1 (de) Hepatitis b inhibitoren
IT1308583B1 (it) Procedimento di consolidamento per terreni ed edifici.
ATE375170T1 (de) Adjuvanskombinationen zur immunisierung und vakzine
TR200103126T2 (tr) Yapısal titremenin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri